Biogen shares are trading higher after partner Eisai initiated the rolling submission of a BLA for lecanemab-irmb for subcutaneous autoinjector for weekly maintenance dosing.
Portfolio Pulse from Benzinga Newsdesk
Biogen shares are trading higher after partner Eisai initiated the rolling submission of a Biologics License Application (BLA) for lecanemab-irmb for subcutaneous autoinjector for weekly maintenance dosing.
May 15, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen shares are trading higher following the news that partner Eisai has initiated the rolling submission of a BLA for lecanemab-irmb for subcutaneous autoinjector for weekly maintenance dosing.
The initiation of the rolling submission of a BLA by Eisai for lecanemab-irmb is a significant milestone that positively impacts Biogen, as it indicates progress in their product pipeline. This news has led to an increase in Biogen's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100